Challenges to the establishment of a monitoring method for the anticoagulant effect of anti-factor Xa inhibitor

被引：0
|
作者：
Nagae, Chiai [1 ]
Ashikaga, Tomoko [1 ,2 ]
Akita, Mieko [1 ]
Yamazaki, Satoshi [3 ]
Takayama, Shigenobu [4 ]
Tatsunami, Shinobu [5 ]
Taki, Masashi [2 ]
机构：
[1] St Marianna Univ, Sch Med, Dept Pediat, Kawasaki, Kanagawa, Japan
[2] Yokohama City Seibu Hosp, Yokohama, Kanagawa, Japan
[3] St Marianna Univ, Dept Clin Lab, Sch Med Hosp, Kawasaki, Kanagawa, Japan
[4] Daito Bunka Univ, Fac Hlth Sci, Tokyo, Japan
[5] St Marianna Univ, Dept Med Stat, Sch Med, Kawasaki, Kanagawa, Japan
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：52 / 52
页数：1
相关论文
共 50 条
  • [1] ANTI-FACTOR XA TESTING FOR QUANTIFYING ANTICOAGULANT EFFECT DUE TO ORAL DIRECT XA INHIBITORS
    Beyer, Jacob
    Trujillo, Toby
    Kiser, Tyree
    CRITICAL CARE MEDICINE, 2015, 43 (12)
  • [2] Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay
    Samama, M. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (04) : 579 - 580
  • [3] A novel microfluidic anti-factor Xa assay device for monitoring anticoagulant therapy at the point-of-care
    Harris, Leanne F.
    Rainey, Paul
    Castro-Lopez, Vanessa
    O'Donnell, James S.
    Killard, Anthony J.
    BIO-MEMS AND MEDICAL MICRODEVICES, 2013, 8765
  • [4] Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): Implications for interventional use
    Tobu, M
    Iqbal, O
    Ma, Q
    Schultz, C
    Jeske, W
    Hoppensteadt, D
    Lewis, B
    Fareed, D
    Fareed, J
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2003, 9 (01) : 1 - 17
  • [5] Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol
    Williams-Norwood, Tanya
    Caswell, Megan
    Milner, Barbara
    Vescera, Joseph C.
    Prymicz, Kelly
    Ciszak, Amy G.
    Ingle, Carol
    Lacey, Christopher
    Stavrou, Evi X.
    AACN ADVANCED CRITICAL CARE, 2020, 31 (02) : 129 - 137
  • [6] IS ANTI-FACTOR XA ACTIVITY IMPORTANT
    HEMKER, HC
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1990, 116 (02): : 268 - 268
  • [7] Synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities
    Xu, Yongmei
    Stancanelli, Eduardo
    Su, Guowei
    Liu, Jian
    GLYCOBIOLOGY, 2023, 33 (11) : 1057 - 1057
  • [8] Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors
    Nakano, Yoshihisa
    Adachi, Shiro
    Hirose, Miku
    Adachi, Takeshi
    Nishiyama, Itsumure
    Yasuda, Kenichiro
    Yoshida, Masahiro
    Kondo, Takahisa
    Murohara, Toyoaki
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [9] Reproducibility of the anti-Factor Xa and anti-Factor IIa assays applied to enoxaparin solution
    Martinez, Celine
    Savadogo, Adama
    Agut, Christophe
    Anger, Pascal
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2013, 81-82 : 138 - 145
  • [10] Challenges of converting to anti-Xa monitoring of IV unfractionated heparin in an oral factor Xa inhibitor era
    Pham, Van Q.
    Chan, Linh L.
    Crumpler, Walter L.
    Wang, Anita
    Jacobson, Alan K.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 47 (04) : 611 - 611
12345